Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,201–1,300 of 2,053
BULGUROĞLU, M., BULGUROĞLU, H. İ., Hepşen, S., Dincer, S., Aslan, C. G., Zorlu, S., Suicmez, S., & Adıgüzel, E. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s565976 · Cited by 1
McInerney, A. M., Schmitz, N., Matthews, M. J., & Deschênes, S. S. (2026) · Diabetic Medicine · doi:10.1111/dme.70269 · Cited by 2
Pescari, D., Mihuta, S., Bena, A., Pui, R., Paul, C., & Stoian, D. L. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1792614 · Cited by 3
“…safety and potential cardiovascular effects require careful patient selection and individualized protein targets, highlighting the need for long-term studies speci fi cally designed to evaluate high-protein diets as a strategy for achieving durable remission of type 2 diabetes mellitus (75, 77).”
Kandalam, S., Benamar, M., Reun, C. L., Rengger, L., Gupta, P., & Nair, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01847-7 · Cited by 1
“…glucose-lowering efficacy with less weight gain and hypoglycaemia compared with intensified insulin regimens, reducing insulin requirements and improving overall metabolic outcomes, while addressing therapeutic inertia and supporting medication-taking behaviour and treatment persistence [4, 8–13].”
InfluentialLin, Y., Du, K., & Tian, J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1711633 · Cited by 1
Fasi, M. A. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2645812 · Cited by 1
“A further perimeter of protection arises from combination and platform claims, which link dual agonists with adjunctive therapies such as Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, metformin, or digital dosing systems [34].”
A sulfated manno-glucuronan ameliorates β-cell dysfunction in type 2 diabetes by targeting ALDH1A3
Zhang, W., Zhang, F., Zou, X., Wu, N., He, S., Lu, L., Xu, C., Xu, W., Jin, W., & Zhou, J. (2026) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2026.125227 · Cited by 1
Wang, S., Sun, B., Zhu, D., Shen, Z., Zhong, X., & Chen, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01852-w · Cited by 1
“It can also contribute added benefits (e.g., weight control, cardiovascular disease risk reduction, and hypoglycaemia management), and simplify treatment with reduced medication burden and improved treatment persistence, adherence, and satisfaction [3, 5, 7–9].”
InfluentialSCORE2-diabetes vs SCORE for evaluation of cardiovascular risk in diabetic patients
Leite, S., Barros, M. S., Trindade, I., Carneiro, C., Silva, J. M., Barbosa, A., & Milheiro, H. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_663_25 · Cited by 1
“[9,10]”
Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness
Nadkarni, A., Deane, A. M., & Plummer, M. P. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001376 · Cited by 3
Umapathysivam, M. M., Araldi, E., Hastoy, B., Dawed, A. Y., Vatandaslar, H., Mayrhofer, J. E., Lindquist, P., Silva, P. N., Goga, A., Trüllinger, G. O., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01630-0 · Cited by 15
Navami, K. S., Thomas, C., & Basutkar, R. S. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.03.008 · Cited by 1
Alhamdan, Y. R., Hsu, J. C., & Lu, C. Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70718 · Cited by 1
Jimoh, A. O., Hudu, S. A., Sabir, A. A., Adamu, A. A., Bello, N., Tahir, A., & Abubakar, N. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/8464330 · Cited by 1
Endocrinology: What You May Have Missed in 2025
Escudero, C., Havranek, K., Cruz, M. M., & Batch, B. C. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00925 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
Guan, Z., Tao, X., Qu, J., Wang, H., Sun, Q., Xiao, Y., Li, Z., Ma, N., Lin, X., Wen, G., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07894-3 · Cited by 1
“…metabolic adaptations across multiple metabolically relevant organs and peripheral energy-demand tissues, whereas established diabetes may involve more diverse metabolic states and comorbidity profiles, leading to less consistent co-variation among the same set of connections [ 3 , 28– 30 ].”
Hopkins, R., de Villiers, E., Weedon, M. N., Shields, B. M., Dennis, J., McGovern, A. P., & Green, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70797 · Cited by 2
Gene–Lifestyle Synergy in Diabetic Retinopathy Development
Yang, S., Xin, Z., Liu, B., Huang, Y., Zhu, Z., Tan, S., He, M., Tham, Y. C., Cheng, C., & Wang, W. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.04.017 · Cited by 2
Do, S., Christensen, K., Inneh, A., Peasah, S. K., & Good, C. B. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.5.625 · Cited by 4
Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes
Ramachandran, A., Batra, J., & Desouza, C. V. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2667324 · Cited by 1
“…insulin therapy) trials have demonstrated that insulin efsitora treat-ment resulted in non-inferior reductions in HbA1c compared with a once-daily basal insulin in adults with type 1 diabetes, insulin-naive type 2 diabetes and type 2 diabetes treated with basal and prandial insulin [3,7,8,10].”
Diabetes distress: What a clinician needs to know – A South Asian perspective
Raza, S. A., Raza, S. I., Irfan, H., Baig, A. M., Ghauri, J. J., Shrestha, D., & HASAN, K. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102116 · Cited by 2
Pal, A. W., Chong, W. L., Huri, H. Z., & Ratnasingam, J. (2026) · Diabetic Medicine · doi:10.1111/dme.70360 · Cited by 1
“3,4 In this context, CGM provides continuous glucose data that support treatment adjustment.”
Shin, M. H., Jeong, J. W., Ha, S. E., Singh, R., Lee, M. Y., Ro, S., & Yu, T. Y. (2026) · Pharmaceuticals · doi:10.3390/ph19050791 · Cited by 1
“…metformin, sulfony-lureas, and insulin—are effective for glycemic control; however, many older agents were limited not only by adverse effects such as weight gain and hypoglycemia but also by their relatively modest impact on durable improvements in diabetes-related morbidity and mortality [2].”
The Triangular Interaction Between Dietary Polyphenols, Gut Microbiota and Type 2 Diabetes
Bayliss, E., Shope, L., Woodfin, S., Mair, G., Becker, M. H., & Moore, W. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114782 · Cited by 1
“…from the American Diabetes Association (ADA) and other international organizations emphasize the importance of early diagnosis through routine screening of high-risk individuals, followed by a stepwise treatment approach beginning with lifestyle modifications and metformin therapy [16,17].”
Abenavoli, L., Loricchio, A. G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D. L., & Luzza, F. (2026) · Medicina · doi:10.3390/medicina62050986 · Cited by 1
The Financial Burden of Prediabetes and Diabetes in Trauma Care Under the G-DRG System
Tercan, E., Tombaz, M., Huber, P., Rollmann, M. F. R., Nussler, A. K., & Ehnert, S. (2026) · Zeitschrift für Orthopädie und Unfallchirurgie · doi:10.1055/a-2861-4883 · Cited by 1
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
“However, evidence that early combination therapy produces more durable glycemic control and better β -cell preservation accumulates [10,280,281].”
Block, C. E. M. D., Benamar, M., Fu, A., Maltesen, R., & Giorgino, F. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103985 · Cited by 1
Carlino, I., Franco, S. D., Colalillo, N., Bisogno, S., Gennari, L., & Palazzuoli, A. (2026) · Biomedicines · doi:10.3390/biomedicines14061289 · Cited by 1
“This phenotype may therefore particularly benefit from therapies capable of modulating systemic inflammation, metabolic dysfunction, and adipose tissue biology [29,63,82–86].”
Tomar, V., Çetin, T. E., Demirezen, A., Akçay, Ö. F., Derici, Ü., Güz, G., & Helvacı, Ö. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02200-5 · Cited by 1
“These recommendations are largely based on safety signals from large cardiovascular and renal outcome trials rather than on direct measurements of steady-state ketonemia across CKD stages in routine practice [5–7, 10, 11].”
InfluentialKuri, K. A. C., Viola, V., & Pozzilli, P. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113389 · Cited by 1
Baron, K. G., Simonsen, S. E., Arones, Y. B., Bermúdez, B., Bombyck, P., Lee, D., Poeliniz, C. M., Mpongo, K., Mukundente, V., Repta, R., et al. (2026) · SLEEP Advances · doi:10.1093/sleepadvances/zpag055 · Cited by 2
“Sleep is now included in the American Heart Association’s Life’s Essential 8 as one of the key behaviors for cardiovascular health [ 7] and in the American Diabetes Association recommendations [ 8].”
Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025)
Romero, R. C. (2026) · BioMolecular Concepts · doi:10.1515/bmc-2025-0059 · Cited by 1
“T2D accounts for the large majority of diabetes cases worldwide and is characterized by insulin resistance in peripheral tissues together with inadequate compensatory insulin secretion from pancreatic β -cells [3].”
InfluentialAl-Maqbali, J. S., Alawi, A. M. A., Osman, A., Al-Farqani, A., Kumar, S., Futisi, A. A., Al-Mamari, A., Al-Zakwani, I., & Za’abi, M. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1883483 · Cited by 2
Cokro, F., Sauriasari, R., Tahapary, D. L., Setiawan, H., Tricaesario, C., Hidayati, N., Djauhari, W., Tandradynata, J., & Soegondo, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0353564 · Cited by 1
Inzucchi, S. E., Ghani, R. A., Deanfield, J. E., Emerson, S. S., Engelmann, M. D. M., Hovingh, G. K., Jeppesen, O. K., Kellerer, M., Mandavya, K., Mann, J. F. E., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag290
Self-citationBraha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
“The ADA–EASD joint report [116] emphasizes a risk-centered approach: • In T2D with atherosclerotic CVD, GLP-1 RA with CV benefits or SGLT2i are recommended early, regardless of HbA1c;”
Alper, A., Fagin, A., Karthikeyan, A., Lerner, M., Gershon, A., Morgan, A. A., Rubinstein, G., Agarwal, R., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00333-0 · Cited by 1
“The combination of basal insulin with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) addresses multiple therapeutic goals simultaneously through complementary mechanisms [4, 5].”
Khedr, A., Raafat, M., Zedan, H. A.-M., & Khedr, M. (2022) · Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · doi:10.21608/aimj.2022.112827.1802 · Cited by 1
Waugh, R., Mireault, A., Rothfus, M. A., Stoneman, S., Lee‐Baggley, D., Lengyel, C. O., Norris, D., Snelgrove‐Clarke, E., Joy, P. R., & Grant, S. (2022) · Healthy Populations Journal · doi:10.15273/hpj.v2i2.11462 · Cited by 1
“For instance, body mass index (BMI; weight in kilograms divided by height in metres squared) has been associated with disease risk (Davies et al., 2022; Health Canada, 2021; Khan et al., 2018; National Heart, Lung, and Blood Institute, n.d.).”
BackgroundUtilizing type 2 diabetes medications outside glycemic parameters – where are we headed?
Malkani, N. P., & Aroda, V. R. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000787 · Cited by 2
Self-citationKwiendacz, H., Nabrdalik, K., Wijata, A. M., Bartman, W., Tabor, E., Olejarz, A., Król, J., Piaśnik, J., Nalepa, J., Stompór, T. P., et al. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16445 · Cited by 3
Somaratne, J., Lesiawan, E., Seaton, T., & Benatar, J. R. (2023) · New Zealand Medical Journal · doi:10.26635/6965.6039 · Cited by 1
Complex metabolic–endocrine syndromes: associations with cardiovascular disease
Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00010-3 · Cited by 2
How SGLT2 inhibitors interact with metformin? A molecular dynamics study
Maleš, V. K., & Požar, M. (2023) · Molecular Simulation · doi:10.1080/08927022.2023.2196346 · Cited by 1
“This group of drugs exhibits a modest impact on glucoregulation, but due to the reduction of overall cardiovascular risk in T2D patients with high cardiovascular risk [6], they have been introduced into the world guidelines for T2D treatment [9].”
BackgroundEstratégias alimentares com redução de carboidratos para o tratamento de Diabetes Mellitus tipo 2.
Santos, J. D. A., & Hessel, L. C. M. L. (2021) · Nutrivisa Revista de Nutrição e Vigilância em Saúde · doi:10.59171/nutrivisa-2021v8e9931 · Cited by 1
Pelu, J. E., Kurniawan, L. B., Widaningsih, Y., Zainuddin, A., Umar, H., Nurahmi, N., & Orno, T. G. (2023) · INDONESIAN JOURNAL OF MEDICAL LABORATORY SCIENCE AND TECHNOLOGY · doi:10.33086/ijmlst.v5i1.3933 · Cited by 4
Die neuen Subtypen des (Prä‑)Diabetes auf dem Weg in die Praxis
Seebauer, L., & Szendrödi, J. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01058-9 · Cited by 2
Lee, H. W., Kang, W. Y., Park, J. S., Lee, J. H., Gwon, M., Yang, D. H., Kim, E. H., Park, S., Yoon, Y., & Seong, S. J. (2023) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2023.31.e10 · Cited by 2
How to apply the Canadian Obesity Clinical Practice Guidelines to people with type 2 diabetes
Pedersen, S. D. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.115 · Cited by 1
Tirzepatide for the treatment of adults with type 2 diabetes
Chaplin, S. (2023) · Prescriber · doi:10.1002/psb.2081 · Cited by 2
AN ASSOCIATION BETWEEN TYPE 2 DIABETES MELLITUS AND A CLINICAL PERIODONTAL PARAMETER: POCKET DEPTH
Mariyum, S., Khan, A. I., Wadud, S., Hakeem, H., Saleem, N., & Younas, M. (2023) · Journal of Khyber College of Dentistry · doi:10.33279/jkcd.v13i1.104 · Cited by 2
The impact of the antidiabetic oral drugs cost on health expenditure in diabetic care in México
Rivas-Vilchis, J. F., Molina-Salazar, R. E., Trejo, C. Z., & Pedroza, J. D. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.24.2.0305 · Cited by 1
Alogliptin and pioglitazone combination for type 2 diabetes mellitus
Моргунова, Т. Б. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-2-47-56 · Cited by 1
From a Glycocentric Approach to Prevention of Multi-Organ Damage in Type 2 Diabetes
Grover‐Páez, F., Gómez, A. M., Suárez, A., & Echauri, A. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002363 · Cited by 2
Васильевна, Ц. О., Evdokimova, N. E., Тимощенко, О. В., & Latyntseva, L. D. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.08.202362 · Cited by 1
Panneerselvam, P., Biswas, D., Singh, H., Kumar, K. D., Kumar, P. R. G., Kalra, P., Revankar, S. Y., & Warrier, S. B. (2023) · Cureus · doi:10.7759/cureus.47190 · Cited by 1
“The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) included this treatment regimen in the therapeutic algorithm for T2DM management [8].”
BackgroundEducating Medical Students on How to Prescribe Anti-Hyperglycaemic Drugs: A Practical Guide
Donker, E. M., Belančić, A., Piët, J. D., Vitezić, D., & Tichelaar, J. (2023) · Diabetology · doi:10.3390/diabetology4040043 · Cited by 1
“…type 2 and its management with anti-hyperglycaemic agents, based on the most recent (inter)national guidelines and evidence-based medicine, such as the guidelines jointly established by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [17].”
BackgroundNeves, L. F., Assunção, S. C., Cunha, A. C., et al. (2023) · Revista chilena de nutrición · doi:10.4067/s0717-75182023000500503 · Cited by 1
The Application of Digital Health in Diabetes Management
Ye, J. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v66i.11711 · Cited by 1
The acceptance and commitment therapy (ACT) reduce stress in patients with type 2 diabetes mellitus
Bistara, D. N., Susanti, S., Pranata, S., & Mustamu, A. C. (2023) · Scripta Medica · doi:10.5937/scriptamed54-45794 · Cited by 5
Klinovszky, A., Buzás, N., Sallay, V., Lengyel, C., & Papp-Zipernovszky, O. (2023) · American Journal of Health Behavior · doi:10.5993/ajhb.47.6.1 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Manjula, S. N., & Krishna Kumar, M. (2024) · South Asian Research Journal of Medical Sciences · doi:10.36346/sarjms.2024.v06i01.003 · Cited by 1
“Further, dipeptidyl peptidase 4 (DPP4) inhibitors are oral medications that inhibit the enzymatic inactivation of endogenous incretin hormones, resulting in glucose-dependent insulin release and a decrease in glucagon secretion [5].”
BackgroundAl‐Omar, H. A., Almodaimegh, H., Omaer, A., Alzubaidi, L. M. Y., Al-Harbi, B., Al-Harbi, I., Hassan, M., & Akhtar, O. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2319458 · Cited by 2
“This is reflected in the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) joint guidelines, ADA’s Standards of Care in Diabetes and the American Heart Association 11–14 .”
Tirzepatid - der Gamechanger in der Diabetestherapie?
Negrean, M. (2024) · Info Diabetologie · doi:10.1007/s15034-023-4901-y · Cited by 1
Larson, S. L., Beaupré, J., Kjelstrom, S., Schwartz, S. S., Hartz, W. H., & Massuda, J. (2024) · Population Health Management · doi:10.1089/pop.2023.0264 · Cited by 3
Beitelshees, A. L., Streeten, E. A., Yazdi, Z. S., Whitlatch, H. B., Mitchell, B. D., Shuldiner, A. R., Montasser, M. E., & Taylor, S. I. (2024) · Clinical and Translational Science · doi:10.1111/cts.13809 · Cited by 2
“1,21,23 In this context, it is noteworthy that many of our research participants in this clinical trial underwent studies to assess pharmacodynamic responses to both sitagliptin and exenatide.”
Scholte, M., Ramaekers, B. L. T., Danopoulos, E., Grimm, S. E., Coves, A. F., Tian, X., Debray, T. P. A., Chen, J., Stirk, L., Croft, R., et al. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01394-8 · Cited by 3
“In practice, it is likely that tirzepatide is used in earlier lines of treatment, according to the European and American Diabetes Associations [11].”
MethodLee, M. M., Khoo, H. S., Krishnasamy, C., Loo, M. E., Wong, S., Cheng, S. C., Bei, Y. T. E., Tan, S. Y., Xie, P., Lee, E. S., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079082 · Cited by 6
Stachteas, P., Patoulias, D., Popovic, D. S., Athanasiadou, P., & Fragakis, N. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.1.6 · Cited by 3
Magdum, M., Unnikrishnan, A., Farishta, F., Balamurugan, R., Murthy, S., Desai, P., Singh, K. P., Barauh, M., Rastogi, A., Kesavadev, J., et al. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0488 · Cited by 1
Yabe, D. (2024) · JMA Journal · doi:10.31662/jmaj.2024-0083 · Cited by 1
Shabbir, S., Amer, M., Mughal, S., Rashid, T., & Habiba (2024) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.10782 · Cited by 4
S odium‐glucose co‐transporter‐2 inhibitors: Writing the next chapter of a unique success story
Festa, A., Saely, C. H., & Drexel, H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15909 · Cited by 1
Insulin injection rotation and Diabetes Mellitus nutritional management education
Narahaubun, I. R., Handayani, D., Kristianto, H., & Kristianto, H. (2024) · Healthcare in Low-resource Settings · doi:10.4081/hls.2024.13065 · Cited by 2
Latent Autoimmune Diabetes in Adults (LADA) Occurring in a Patient with Primary Biliary Cholangitis
Lee, B., Pak, K., & Pockros, P. J. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.09.012 · Cited by 1
Hamblin, P. S., Earnest, A., Russell, A. W., Talic, S., Zomer, E., & Zoungas, S. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101207 · Cited by 1
“7,8 Given the rapidly increasing use of SGLT2i and GLP-1 RAs over the past decade, 9 our study sought to explore whether insulin utilisation had been impacted, as this has implications for future global insulin requirements and costs.”
BackgroundGudibanda, S., Govardhane, S., Kaloo, S., Shah, S., Miglani, V., & Verma, G. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_129_24 · Cited by 2
Каронова, Т. Л., Murasheva, A. V., Тимкина, Н. В., Станиславовна, Ф. О., & Shlyakhto, E. V. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-404 · Cited by 1
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0389 · Cited by 1
“…Konsensus Bericht der „ American Diabetes Association “ (ADA) und der „ European Association for the Study of Diabetes “ (EASD) aus dem Jahr 2022 [7] definiert für die meisten Menschen mit Typ-2-Diabetes eine Gewichtsreduktion von mindestens 5 – 15% als Therapieziel, wobei eine 10 – 15%ige…”
Петрухина, И. К., Lazarev, A. M., Ryazanova, T. K., et al. (2024) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2024.281 · Cited by 1
Seidel‐Jacobs, E., Kohl, F., Rosenbauer, J., Schulze, M. B., Kuß, O., & Rathmann, W. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2024.12.009 · Cited by 2
A Consensus Report on Management of Type 2 Diabetes Mellitus in Iran
Esteghamati, A., Malek, M., Hosseinpanah, F., Hadaegh, F., Afkhami‐Ardekani, M., Meybodi, H. R. A., Dabbaghmanesh, M. H., Ghaemi, F., Jahed, S. A., Kalbasi, S., et al. (2024) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.39.13 · Cited by 1
“Recommendation 2: Metformin is recommended as the first line treatment option in people with T2MD and without established ASCVD, high-risk indicators for ASCVD, HF, or CKD (9, 17, 20-23).”
Ribas-Seguí, D., Forcadell-Peris, M. J., Vila-Córcoles, Á., de Diego‐Cabanes, C., Gondar, O. O., Luján, F. M., & Satué-Gracia, E. M. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02826-w · Cited by 1
“Typically these predictive models analyze individual prognostic factors in isolation but ignore the interaction between them, often overlooking their interactions, such as those observed in several studies involving age and gender [6].”
Resumen ejecutivo del documento «Hospital de Día de Diabetes. Propuesta de valor»
Martín, F. J. E. S., Lesmes, I. B., Peralta, F. G., et al. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501601 · Cited by 1
Treml, J., Václavík, J., Molčanová, L., Čulenová, M., Hummelbrunner, S., Neuhauser, C., Dirsch, V. M., Weghuber, J., & Šmejkal, K. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c11398 · Cited by 2
Comparative evaluation of SGLT-2i and GLP-1RA neuroprotective properties in type 2 diabetic patients
Murasheva, A. V., Каронова, Т. Л., Станиславовна, Ф. О., Тимкина, Н. В., Fedotova, A. D., Grineva, E. N., & Shlyakhto, E. V. (2025) · Diabetes Mellitus · doi:10.14341/dm13255 · Cited by 2
O’Neill, S., Bidulka, P., Lugo-Palacios, D. G., Carroll, O., Leiva-Escobar, I., Silverwood, R. J., Briggs, A. H., Adler, A., Khunti, K., & Grieve, R. (2025) · Diabetologia · doi:10.1007/s00125-025-06447-x · Cited by 2
“National guidelines [4] and international guidance [39] for treatment of people with type 2 diabetes do not provide nuanced recommendations as to which patients benefit most from a given treatment since most of the relevant RCTs only assess average treatment effects in selected trial populations…”
Silvinato, A., Floriano, I., & Bernardo, W. M. (2025) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2025d714 · Cited by 1
“These hormonal changes enhance pancreatic beta-cell function and insulin secretion, supporting the integration of bariatric surgery into the therapeutic paradigm for T2DM 14,15 .”
Joshi, M., Kim, K., Pickard, A. S., Sharp, L. K., Gerber, B. S., & Touchette, D. R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf153 · Cited by 1
Lima, R. P. E., Viana, K. S. S., Silva, P. G. B., Cota, L. O. M., & Costa, F. O. (2025) · Journal of Applied Oral Science · doi:10.1590/1678-7757-2025-0121 · Cited by 3
Tirzepatide: a dual approach to combat obesity and obstructive sleep apnea
Naseem, S., Afreen, S., Fareha, S., Pushpa, C., & Reja, M. H. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20252496 · Cited by 1
Tichler, A., Hertroijs, D. F. L., van Mastrigt, G. A. P. G., Brouwers, M. C. G. J., Ruwaard, D., & Elissen, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0300944 · Cited by 1
Re-imagining Oral Semaglutide in Routine Clinical Practice: Indian Expert Panel Recommendations
Jagadeesha, A., Saboo, B., WANGNOO, S. K., Gangopadhyay, K. K., Kesavadev, J., Bantwal, G., Kalra, P., Thacker, H. P., & PATANGE, S. A. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_18_25 · Cited by 1
Guan, H., Jiang, H., Yuan, H., Sun, J., Xu, J., & Ji, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70047 · Cited by 3
Zhu, Q., Wang, Y., Yan, S., & Liu, Y. (2025) · Medicine · doi:10.1097/md.0000000000044488 · Cited by 3
“[41] This study likewise presented some limitations.”
Голубев, С. А. (2025) · Рецепт · doi:10.34883/pi.2025.28.5.003 · Cited by 1
Experience with insulin detemir for type 2 diabetes in older people and people with comorbidities
Davies, M. J., Alibegovic, A. C., Jensen, A. B., Munikrishnappa, R., & Braae, U. C. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103327 · Cited by 1
Self-citation
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.